Jos University Teaching Hospital
Jos, Plateau State, 930001, Nigeria
NCT Number: NCT00949832
The purpose of this study is:
1. To compare the response of rickets to calcium with and without vitamin D. 2. To assess whether vitamin D increases calcium absorption in calcium deficiency rickets. 3. To compare the response of children with and without rickets to orally administered vitamin D3 and vitamin D2 4. To identify mutations that influence calcium and vitamin D metabolism among families of children with rickets in Nigeria and Bangladesh. 5. To assess the functional status of the 25-hydroxylase enzyme in families possessing a 25-hydroxylase mutation.
Looking for future studies?
Notify Me6 month–16 year
All sexes
Interventional
Phase 4
Jos, Plateau State, 930001, Nigeria
Previous studies of Nigerian children with rickets demonstrated the superiority of calcium over vitamin D in producing healing. It is not known whether the addition of vitamin D to calcium will produce a better response to treatment than calcium alone in Nigerian children. A previous study suggested the possibility that vitamin D may augment the effect of calcium. We will compare the response of rickets to calcium with and without vitamin D. In addition, very little human data clearly demonstrates the effect of supplemental vitamin D on calcium absorption. We will assess whether oral vitamin D increases the already high calcium absorption even further.
Recent published data indicate that the increase in serum 25-hydroxyvitamin D may be more sustained with vitamin D3 than with vitamin D2. We will compare the response of Nigerian children with and without rickets to orally administered vitamin D3 and vitamin D2.
Because nutritional rickets tends to run in families, we will also examine amplified DNA for evidence of mutations that influence calcium and vitamin D metabolism among families of children with rickets in Nigeria and Bangladesh. Families possessing a recently identified 25-hydroxylase mutation will be given oral vitamin D2 and vitamin D3 to determine the functional status of the 25-hydroxylase enzyme.
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Vitamin D 50,000 IU orally once monthly for 6 months; Calcium carbonate (as powdered limestone) 500 mg orally twice daily for 6 months
Other names: ergocalciferol
Calcium carbonate (as powdered limestone) 500 mg orally twice daily for 6 months; Vitamin B complex (used as placebo) 1 tablet monthly for 6 months
Other names: limestone
50,000 IU given orally once
Other names: ergocalciferol
Vitamin D3 50,000 IU given orally once
Other names: cholecalciferol
Time frame: 6 months
Time frame: 6 months
Time frame: 6 months
Time frame: 6 months
Time frame: 2 weeks
Time frame: 1 week
Mayo Clinic
Other
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT05310760
Avitaminosis, Bone Diseases
Cairo, Egypt
View Trial DetailsNCT01578434
Avitaminosis, Deficiency Diseases
View Trial DetailsNCT03747523
Avitaminosis, Bone Diseases
Winston-Salem, North Carolina, United States
View Trial DetailsNCT02301520
Avitaminosis, Bone Diseases
Pierre Payen, Haiti
View Trial Details